IMAB I-MAB ADS (N Shares)

I-Mab to Participate in Leerink Partners Global Healthcare Conference

I-Mab to Participate in Leerink Partners Global Healthcare Conference

ROCKVILLE, Md., Feb. 18, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a US-based, global biotech company, exclusively focused on the development of precision immune-oncology agents for the treatment of cancer, today announced that members of I-Mab’s management will participate in one-on-one meetings at the Leerink Partners Global Healthcare Conference in Miami, Florida on Tuesday and Wednesday, March 11-12, 2025.

About I-Mab

I-Mab (NASDAQ: IMAB) is a US-based, global biotech company, exclusively focused on the development of precision immuno-oncology agents for the treatment of cancer. I-Mab has established operations in Rockville, Maryland, and Short Hills, New Jersey. For more information, please visit  and follow us on  and .

I-Mab Investor & Media Contacts

PJ Kelleher

LifeSci Advisors







EN
18/02/2025

Underlying

IMABI-MAB ADS (N Shares)

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on I-MAB ADS (N Shares)

 PRESS RELEASE
Free
IMAB I-MAB ADS (N Sh...

NovaBridge Presents Positive Ragistomig Phase 1 Dose Expansion Data at...

NovaBridge Presents Positive Ragistomig Phase 1 Dose Expansion Data at ESMO-IO Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients with advanced or metastatic solid tumors, including those who have relapsed or are refractory to checkpoint inhibitors, a multi-billion dollar pillar of cancer care, hampered by widespread resistanceThe study achieved its objective, as the new Q6W extended dosing interval produced encouraging anti-tumor efficacy and immunological data in prior immune-oncology refractory or relapsed patients including anti-PD- (L)1 checkpoint inhibitor, ...

December 10, 2025 1 EN
 PRESS RELEASE
Free
IMAB I-MAB ADS (N Sh...

NovaBridge Announces Presentation of Ragistomig Expanded Phase 1 Data ...

NovaBridge Announces Presentation of Ragistomig Expanded Phase 1 Data at ESMO-IO Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients who are relapsed or refractory to checkpoint inhibitors, a multi-billion dollar drug class hampered by widespread resistanceThe Phase 1 ragistomig study achieved its objective, as the new Q6W extended dosing interval produced strong anti-tumor efficacy in PD-L1-non-responders, with an improved safety profileThe interim results, including immunological data on CD8+ cell proliferation and memory T-cell activation, are expected to be pre...

December 4, 2025 1 EN
 PRESS RELEASE
Free
IMAB I-MAB ADS (N Sh...

NovaBridge’s Visara Subsidiary Appoints Distinguished Ophthalmology Le...

NovaBridge’s Visara Subsidiary Appoints Distinguished Ophthalmology Leaders as Chief Medical Officer and Scientific Advisory Board Chair to Drive VIS-101 Forward Cadmus C. Rich, MD, MBA, as Chief Medical Officer, and Carlos Quezada-Ruiz, MD, FASRS, as Chair of the Scientific Advisory Board, bring invaluable clinical development expertise to VIS-101 ProgramThe ability to attract seasoned ophthalmology leaders highlights the compelling opportunity for VIS-101, and underscores our commitment to assembling a world-class teamVIS-101, a novel bifunctional biologic targeting VEGF-A/ANG2, has the p...

November 21, 2025 1 EN
 PRESS RELEASE
Free
IMAB I-MAB ADS (N Sh...

NovaBridge Subsidiary Visara Assigns Its Exclusive License to Everest ...

NovaBridge Subsidiary Visara Assigns Its Exclusive License to Everest Medicines for VIS-101 in Greater China and Certain Other Asian Countries NovaBridge subsidiary Visara assigned its exclusive license to Everest Medicines to accelerate the development of potential best-in-class therapy for wet AMD, VIS-101, leveraging Everest Medicines’ strong clinical and commercialization expertise in Greater China and other Asian marketsNovaBridge also named Mr. Ian Woo, President and Chief Financial Officer of Everest Medicines, to its Board of Directors, bringing substantial expertise in internationa...

October 29, 2025 1 EN
 PRESS RELEASE
Free
IMAB I-MAB ADS (N Sh...

I-MAB (Nasdaq: IMAB) Transitions to NovaBridge Biosciences (Nasdaq: NB...

I-MAB (Nasdaq: IMAB) Transitions to NovaBridge Biosciences (Nasdaq: NBP) with Trading Effective October 30, 2025 New Brand and Logo to Reflect Strategic Transformation to a Global Biotech Platform New corporate brand reflects strategic transformation to a global biotech platform accelerating access to innovative medicines for patients worldwideStrategy centers on broadening access to global capital and innovation through a planned Hong Kong initial public offering (IPO), and holding dual listings on Nasdaq and Hong Kong Stock Exchange (HKEX)Consistent with the new hub-and-spoke business mod...

October 29, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch